Patients with myelodysplastic syndromes (MDS) face varying progression risks based on clinical factors such as low hemoglobin levels and platelet counts, according to an abstract presented at the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, California.
The study, which analyzed data from patients enrolled in the Myelodysplastic Syndromes Natural History Study (MDS NHS), For this analysis, 582 MDS patients and 505 at-risk MDS patients were included. MDS patients were more likely to be male, older, and had lower baseline levels of hemoglobin, platelets, and absolute neutrophil counts compared to at-risk MDS patients.
The investigators found that 18.5% of participants experienced disease progression. Annual progression rates were 8% for those with MDS and 2% for individuals classified as at risk of MDS (AR-MDS). Among high-risk MDS patients, progression was most pronounced in the first year following diagnosis, with 33% advancing to more severe disease stages.
“The MDS NHS provides an incomparable opportunity to address the critical clinical challenges of management and prevention of MDS progression across its spectrum,” the authors, led by Amy Dezern, MD, MHS, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, wrote in the abstract.
Reference
DeZern A, Otterstatter M, Gillis M. Progression of Myelodysplastic Syndromes in the MDS Natural History Study (MDS NHS). Abstract 1831. Presented at the American Society of Hematology Annual Meeting and Exposition; San Diego, California.
